Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Therapeutic Drug Carrier Systems
Factor de Impacto: 2.9 Factor de Impacto de 5 años: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimir: 0743-4863
ISSN En Línea: 2162-660X

Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2017018714
pages 1-64

Polymeric Immunonanoparticles Mediated Cancer Therapy: Versatile Nanocarriers for Cell-Specific Cargo Delivery

Namdev L. Dhas
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
Ritu R. Kudarha
The Maharaja Sayajirao University of Baroda, Gujarat, India
Niyati S. Acharya
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
Sanjeev R. Acharya
SSR College of Pharmacy, Sayli, Silvassa, Dadra Nagar and Haveli, India


The major drawback with conventional therapeutic approaches for cancer therapy is decreased efficacy and redundant therapy associated toxicity and side effects causing increased patient discomfort. With the aim of minimizing these limitations, a vast amount of attention has been given to targeted nanocarrier–based drug delivery systems that possess a several-fold advantage over conventional therapy. Increased research in targeted nanoparticulate systems has led to the development of immunonanoparticles with enhanced efficacy and targeting efficiency along with decreased drug-resistant cancer- and dose-related toxicity. These immunonanoparticle- based therapies, which can be extended to immunotherapy, have gained wide attention, but few formulations will be approved by regulatory agencies in the near future. This review details the various immunonanoparticle systems explored in cancer therapy, with particular emphasis on polymeric nanoparticles. This review describes the mechanisms of immunotherapy and the pathways for targeting dendritic cells for immunotherapy. It also focuses on present status of clinical trials of immunonanoparticles and related patents, as well as various FDA-approved monoclonal antibodies (mAbs) for immunotherapy. Toxicity issues related to immunonanoparticles along with regulatory guidelines for these therapeutic nanoparticles are also discussed.

Articles with similar content:

Formulation and Physiological Factors Influencing CNS Delivery upon Intranasal Administration
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.23, 2006, issue 4
Tushar Vyas, Mansoor M. Amiji, Sandip B. Tiwari
Oral Insulin: Current Status, Challenges, and Future Perspectives
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 4
Gaurav Gupta, Yap Yenese, Jestin Chellian, Chew Chian Wei, Dinesh Kumar Chellappan
Nanostructured Materials in Drug and Gene Delivery: A Review of the State of the Art
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 2
Krutika Sawant, Kailash C. Petkar, Sandip S. Chavhan, Snezana Agatonovik-Kustrin
Nano-Aggregates: Emerging Delivery Tools for Tumor Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 6
Vinod Kumar Sharma, Ankit Jain, Vandana Soni
Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 5
Min Chen, Ying Fan, Xuefeng Xia, Wen Wu, Philippe Maincent, Jinqiang Zhang